Incidences and risk factors of first-line HAART discontinuation: a limitation to the success of the "seek, test, treat, and retain" strategy?
Keita, Momory; Perbost, Isabelle; Pugliese-Wehrlen, Sylvia; Abel, Sylvie; Pugliese, Pascal; Enel, Patricia; Cuzin, Lise; Lang, Thierry; Delpierre, Cyrille.
; 26(8): 1058-69, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24517736
Exploring concentration response in HIV pre-exposure prophylaxis to optimize clinical care and trial design.
Temporal trends in the discontinuation of first-line antiretroviral therapy.
Comprehensive Ryan White Assistance and Human Immunodeficiency Virus Clinical Outcomes: Retention in Care and Viral Suppression in a Medicaid Nonexpansion State.
Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.
Durable Viral Suppression and Transmission Risk Potential Among Persons With Diagnosed HIV Infection: United States, 2012-2013.
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.
Les CECOS : des missions et une expertise.
Antiretroviral Agents: Looking for the Best Possible Chemotherapeutic Options to Conquer HIV.
Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
Low dose versus high dose stavudine for treating people with HIV infection.